DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the CIDP Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
Stay ahead in the CIDP Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic Inflammatory Demyelinating Polyneuropathy Overview
Chronic inflammatory demyelinating polyneuropathy is a rare neurological disorder characterized by inflammation and damage to the protective covering of nerves, known as the myelin sheath. This damage disrupts the communication between nerves and muscles, leading to progressive weakness and impaired sensory function. CIDP is clinically classified into typical and atypical forms. The typical form, the most common, involves symmetrical polyneuropathy, where both proximal and distal muscles are equally affected, leading to widespread weakness and sensory deficits. Symptoms usually progress gradually, but severity varies among patients, impacting walking, fine motor skills, and daily activities.
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving CIDP epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence
Chronic Inflammatory Demyelinating Polyneuropathy Marketed Drugs
HYQVIA is an immunostimulant combining human immunoglobulin (IG 10%) with recombinant human hyaluronidase, enabling SC for easier administration. This treatment offers a convenient alternative to IVIg by allowing larger-volume, less frequent SC due to enhanced absorption. HYQVIA modulates the immune system to reduce autoimmune damage to the nerves in CIDP. In January 2024, the US FDA approved HYQVIA for the maintenance treatment of CIDP in adults. The European Commission also approved it for the same purpose, and the UK’s MHRA granted approval in March 2024. Takeda filed for approval in Japan in August 2024.
VYVGART HYTRULO is a coformulation of efgartigimod alfa and recombinant human hyaluronidase, designed to enhance SC absorption. It works by reducing autoantibodies implicated in CIDP through inhibition of the FcRn receptor. Approved by the US FDA in June 2024, it received orphan drug designation for CIDP in 2021. This therapy offers a convenient option for maintaining remission via SC administration.
GAMMAGARD LIQUID/KIOVIG is a ready-to-use IV formulation of IVIg derived from human plasma, offering a broad spectrum of antibodies. It works by modulating the immune system, reducing inflammation, and preventing further nerve damage in CIDP. Clinical studies have shown its effectiveness in improving muscle strength and functional ability, helping manage symptoms and maintain long-term stability. It was approved by the US FDA in January 2024 for adults with CIDP. In May 2019, KIOVIG was also approved in the EU for treating CIDP in adults, children, and adolescents (0–18 years).
Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
Riliprubart (SAR445088) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in CIDP. Riliprubart has convenient subcutaneous route of administration. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of CIDP.
Batoclimab is a human monoclonal antibody directed against the Neonatal Crystallizable Fragment Receptor (FcRn), with potential immunomodulating activity. Upon administration, batoclimab targets and binds to FcRn at the Immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, batoclimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes. Immunovant reported topline results in March 2025 from its Phase IIb study of batoclimab in CIDP, showing meaningful improvements in disability scores during the initial 12-week period. Patients with deeper reductions in IgG levels demonstrated higher responder rates.
Get In-Depth Knowledge on CIDP Market Trends and Forecasts with DelveInsight @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic inflammatory demyelinating polyneuropathy, though classified as a rare disease, has gained increasing recognition in recent years. This is largely due to improvements in diagnostic techniques, greater awareness among healthcare professionals, and a deeper understanding of the condition. Management of CIDP typically involves a combination of pharmacological therapies and supportive interventions, with the primary objectives to suppress inflammation, modulate immune responses, and improve motor and sensory function.
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Landscape
The treatment landscape for CIDP has advanced with a multi-faceted approach, combining medications, and supportive care. Corticosteroids, such as prednisone and dexamethasone, are often the initial treatment. While they are effective in inducing remission, they carry a high risk of significant long-term side effects, including osteoporosis, weight gain, and increased susceptibility to infections. These adverse effects often necessitate combination therapies with steroid-sparing agents, which may not be universally effective. Plasma exchange has shown short-term efficacy in removing harmful autoantibodies and improving symptoms. However, it is an invasive procedure that requires highly specialized centers and trained personnel, limiting its accessibility, IVIg has become the gold standard due to its demonstrated efficacy in long-term disease control and symptom improvement. Despite this, IVIg is costly, time-consuming, and heavily reliant on donor plasma, raising concerns about its long-term availability.
Unlock Strategic Insights with DelveInsight’s Comprehensive CIDP Market Report @ CIDP Market Drivers and Barriers
Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market
Table of Content
1. Key Insights
2. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction
3. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance
4. Chronic Inflammatory Demyelinating Polyneuropathy Methodology
5. Chronic Inflammatory Demyelinating Polyneuropathy Executive Summary
6. Chronic Inflammatory Demyelinating Polyneuropathy Disease Background and Overview
7. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population
8. Chronic Inflammatory Demyelinating Polyneuropathy Treatment
9. Diagnostic and Treatment Guidelines for Chronic Inflammatory Demyelinating Polyneuropathy
10. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
11. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
12. Chronic Inflammatory Demyelinating Polyneuropathy Approved Therapies
13. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies
14. Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis
15. Chronic Inflammatory Demyelinating Polyneuropathy KOL Views
16. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers
17. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers
18. Chronic Inflammatory Demyelinating Polyneuropathy SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
